• Biden administration moves to establish ‘guardrails’ for telehealth prescriptions
    The Biden administration has proposed new rules that will require patients to have an in-person medical evaluation before being prescribed most prescription medications by their doctors, with limited exceptions, according to a statement released on Friday. Learn more
  • Biden-⁠Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States
    Xylazine’s growing role in overdose deaths nationwide prompts Administration to make this designation for the first time in U.S. history.

    Today, Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), has officially designated fentanyl adulterated or associated with xylazine as an emerging threat to the United States. Xylazine is a non-opioid tranquilizer approved by the Food and Drug Administration (FDA) for veterinary use but not human use. This designation comes after careful review of the impact of xylazine on the opioid crisis, including its growing role in overdose deaths in every region of the United States. Learn more
  • The Biden-Harris Administration Takes Critical Action to Make Naloxone More Accessible and Prevent Fatal Overdoses from Opioids Like Fentanyl
    Today, the U.S. Food and Drug Administration (FDA) approved the first nonprescription, “over-the-counter” (OTC) naloxone nasal spray, Narcan. Naloxone – a medicine that can reverse an opioid-related overdose – has been shown to be a critical tool to prevent fatal overdoses, connect more people to treatment for substance use disorder, and save lives. This action by the Biden-Harris administration to make this naloxone product available without a prescription will pave the way for the life-saving medication to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations, as well as online. Learn more
  • Medicaid member eligibility review actions to resume
    As a result of the recently passed federal spending bill, the continuous enrollment provisions that the Indiana Health Coverage Programs (IHCP) has been following since March 2020 will end as of March 31, 2023. This means that regular determinations of coverage will begin again and actions to adjust, reduce or eliminate coverage will be allowed beginning in April 2023. Learn more
  • Request for Funding Announcement – RFF-2023-007 for State of Indiana Opioid Settlement Match Grant
     This is a Request for Funding announcement (RFF) issued by the Family and Social Services Administration, Division of Mental Health & Addiction in conjunction with the Executive Director for Drug Prevention, Treatment and Enforcement. The date for this project is July 2023 through June 2025.  Learn more